The potential development of drug resistance in rheumatoid arthritis patients identified with p53 mutations

Congling Qiu; Joyce Tsz Wai Chan; David Wei Zhang; Io Nam Wong; Yaling Zeng; Betty Yuen Kwan Law; Simon Wing Fai Mok; Ivo Ricardo De Seabra Rodrigues Dias; Wenfeng Liu; Liang Liu; Vincent Kam Wai Wong

doi:10.1016/j.gendis.2023.02.007

您当前的位置：

首页 >

文章列表页 >

The potential development of drug resistance in rheumatoid arthritis patients identified with p53 mutations

Rapid Communications | 更新时间：2024-02-04

- The potential development of drug resistance in rheumatoid arthritis patients identified with p53 mutations
- The potential development of drug resistance in rheumatoid arthritis patients identified with p53 mutations
- Genes & Diseases 2023年1卷第6期页码：2252-2255
- 作者机构：
  
  1. . Neher's Biophysics Laboratory for Innovative Drug Discovery, State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Macau SAR,Dr,China,999078
  2. Department of Public Health and Preventive Medicine, School of Medicine, Jinan University,Guangdong,Guangzhou,China,510000
  3. Faculty of Medicine, Macau University of Science and Technology, Macau SAR,China,999078
  4. School of Biotechnology and Health Sciences, Wuyi University,Guangdong,Jiangmen,China,529000
- 作者简介：
- 基金信息：
- DOI：10.1016/j.gendis.2023.02.007
  中图分类号：
- 纸质出版日期：2023，
  
  网络出版日期：2023-11-1，
扫描看全文
The potential development of drug resistance in rheumatoid arthritis patients identified with p53 mutations[J]. Genes & Diseases, 2023,1(6):2252-2255.

Congling Qiu, Joyce Tsz Wai Chan, David Wei Zhang, et al. The potential development of drug resistance in rheumatoid arthritis patients identified with p53 mutations[J]. Genes & Diseases, 2023,1(6):2252-2255.
The potential development of drug resistance in rheumatoid arthritis patients identified with p53 mutations[J]. Genes & Diseases, 2023,1(6):2252-2255. DOI： 10.1016/j.gendis.2023.02.007.

Congling Qiu, Joyce Tsz Wai Chan, David Wei Zhang, et al. The potential development of drug resistance in rheumatoid arthritis patients identified with p53 mutations[J]. Genes & Diseases, 2023,1(6):2252-2255. DOI： 10.1016/j.gendis.2023.02.007.

摘要

Abstract

关键词

Keywords

references

1 J.S. Smolen, D. Aletaha, A. Barton, et al.Rheumatoid arthritis Nat Rev Dis Prim, 4 (2018), Article 18001

2 H. Taubert, B. Thamm, A. Meye, et al.The p53 status in juvenile chronic arthritis and rheumatoid arthritis Clin Exp Immunol, 122 (2) (2000), pp. 264-269

3 C. He, L. Li, X. Guan, et al.Mutant p53 gain of function and chemoresistance: the role of mutant p53 in response to clinical chemotherapy Chemotherapy, 62 (1) (2017), pp. 43-53

4 Z. Han, D.L. Boyle, Y. Shi, et al.Dominant-negative p53 mutations in rheumatoid arthritis Arthritis Rheum, 42 (6) (1999), pp. 1088-1092

5 V.K.W. Wong, C. Qiu, S.W. Xu, et al.Ca2+ signalling plays a role in celastrol-mediated suppression of synovial fibroblasts of rheumatoid arthritis patients and experimental arthritis in rats Br J Pharmacol, 176 (16) (2019), pp. 2922-2944

查看原文

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

暂无数据